Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ampio Pharmaceuticals Inc AMPE

Healthcare
Ampio Pharmaceuticals, Inc. is a drug discovery and development company. The Company is focused on combining scientific, clinical, and manufacturing capabilities to develop therapies aimed at treating conditions for which limited treatment options exist.

Recent & Breaking News (OTCPK:AMPE)

Ampio Pharmaceutical's Application to the FDA for a Clinical Study of Ampion(TM) to Treat COVID-19 Induced Acute Respiratory Distress Syndrome (ARDS) featured in FOX News (VIDEO)

PR Newswire April 2, 2020

Ampio Suspends Patient Enrollment in its Phase 3 Study of Ampion for Severe Osteoarthritis of the Knee and Explores Other Options to Complete Trial

PR Newswire March 24, 2020

Ampio is Preparing an Expanded Access FDA protocol to Study Nebulized Ampion as a Treatment for Moderate to Severe Acute Respiratory Distress Syndrome Associated with COVID-19

PR Newswire March 24, 2020

Ampio Provides Corporate Update

PR Newswire February 21, 2020

Ampio Provides Update on AP-013 Phase III Clinical Trial and Annual Meeting Conference Call Number

PR Newswire December 4, 2019

Ampio Provides Update on Continued Progress of AP-013 Phase III Clinical Trial and Manufacturing Facility

PR Newswire October 10, 2019

Ampio Retains Legal Counsel for Transaction Advisory Committee

PR Newswire September 18, 2019

Ampio Pharmaceuticals Retains Financial Advisor and Appoints Transaction Advisory Committee

PR Newswire August 22, 2019

Ampio Pharmaceuticals Updates Progress of SPA Clinical Trial

PR Newswire July 25, 2019

Ampio Appoints Moss Adams LLP as the Company's New Independent Auditor

PR Newswire July 11, 2019

Ampio Appoints Dan Stokely as the Company's new Chief Financial Officer

PR Newswire July 10, 2019

Ampio Pharmaceuticals Announces Closing of $12 Million Public Offering

PR Newswire June 19, 2019

Ampio Pharmaceuticals Announces Pricing of Public Offering

PR Newswire June 17, 2019

Ampio Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

PR Newswire June 14, 2019

Ampio Regulatory and Clinical Update

PR Newswire June 14, 2019

Ampio Clinical, Regulatory and Corporate Update

PR Newswire May 22, 2019

Ampio Pharmaceuticals Provides Regulatory Update

PR Newswire April 29, 2019

Ampio Pharmaceuticals Provides Corporate Update

PR Newswire March 26, 2019

Ampio Updates Regulatory Status for Ampion

PR Newswire March 6, 2019

Ampio Updates Status of Pivotal Clinical Trial of Ampion to be Carried Out Under a SPA

PR Newswire February 6, 2019